TL;DR
This pilot study investigated the combination of apatinib and irinotecan for patients with recurrent high-grade glioma, a notoriously difficult-to-treat brain cancer. The findings suggest this combination is a promising therapeutic option, showing encouraging response rates and manageable side effects, warranting further investigation in larger trials.
What Problem Does This Paper Address?
Malignant gliomas, particularly glioblastoma (GBM), are aggressive brain tumors with a poor prognosis. Even after standard treatments like surgery, radiation, and chemotherapy (temozolomide), these tumors often recur. Recurrent gliomas present a significant challenge, with limited effective treatment options and a median survival of only 6-8 months post-relapse. The high vascularity of these tumors has made targeting the vascular endothelial growth factor (VEGF) pathway a key strategy. While bevacizumab, an anti-VEGF antibody, has shown some efficacy, there's a continuous need for novel and more effective therapies. This study aims to evaluate a new approach using apatinib, a small-molecule tyrosine kinase inhibitor targeting VEGF receptor 2 (VEGFR-2), in combination with irinotecan, a chemotherapy agent, for patients with recurrent high-grade glioma.
Methods
This was a multicentric, single-arm, open-label, pilot Phase II clinical trial. Ten patients with recurrent high-grade glioma who had relapsed after temozolomide treatment were enrolled. The treatment regimen involved oral apatinib (500 mg daily) in conjunction with irinotecan (125 mg/m² or 340 mg/m² depending on enzyme-inducing antiepileptic drug use) for six cycles. Following these cycles, patients continued with apatinib as maintenance therapy. The primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and disease control rate (DCR) as secondary endpoints. Response was assessed using RECIST 1.1 criteria via MRI and clinical evaluation. Statistical analysis for survival was performed using the Kaplan-Meier method.
Datasets
Not discussed in the paper. The study involved patient data collected during the clinical trial.
Key Insights and Ideas
- Targeting Angiogenesis in Recurrent Glioma: The study builds on the understanding that malignant gliomas are highly vascular and that targeting the VEGF pathway can be beneficial. It explores a novel combination therapy by combining a VEGFR-2 inhibitor (apatinib) with a chemotherapy agent (irinotecan).
- Apatinib's Potential Advantages: Apatinib, as an oral small-molecule TKI, is hypothesized to have advantages over bevacizumab, including potential to promote tumor cell apoptosis via intracellular autocrine VEGF signaling and the ability to reverse multidrug resistance (MDR) by inhibiting ABC transporters like P-glycoprotein. This is particularly relevant for recurrent tumors that may have developed resistance to prior therapies.
- Promising Efficacy in a Challenging Population: Despite the small sample size, the combination therapy demonstrated encouraging efficacy, with a notable objective response rate and disease control rate, suggesting it can effectively manage recurrent high-grade gliomas.
- Manageable Toxicity Profile: The combination therapy was generally well-tolerated, with most adverse events being grade 1 or 2 and manageable through dose adjustments or interruptions. This is crucial for maintaining treatment adherence in patients with a serious illness.
Key Results
- Efficacy: Of the 9 patients available for efficacy evaluation, 5 achieved partial response (PR), 2 had stable disease (SD), and 2 had progressive disease (PD).
- Objective Response Rate (ORR): 55% (5/9)
- Disease Control Rate (DCR): 78% (7/9)
- Median Progression-Free Survival (mPFS): 8.3 months.
- Safety: The most common adverse events were gastrointestinal reactions (31.8%), hypertension (22.7%), and myelosuppression (18.0%). Three patients required dose reduction of apatinib due to toxicity. One patient discontinued treatment due to severe hypertension. No drug-related AEs were reported as occurring in this study.
Limitations and Future Work
- Limitations: The primary limitation acknowledged by the authors is the small sample size (10 patients) of this pilot study. This restricts the generalizability of the findings and necessitates caution in interpretation. The study was also a single-arm trial, lacking a control group for direct comparison.
- Future Work: The authors strongly recommend larger, prospective clinical studies with an adequate sample size to validate these promising results. Further investigation is needed to confirm the efficacy and safety of apatinib combined with irinotecan in a broader patient population with recurrent high-grade glioma.
Summary updated